Sound waves guided by MRI aim to zap prostate tumors with fewer side effects

NCT ID NCT03814252

Ongoing Disease control Sponsor: Turku University Hospital Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study tests a device that uses ultrasound energy guided by MRI to precisely destroy prostate cancer tumors while sparing healthy tissue. 62 men with localized prostate cancer will receive the treatment. The goal is to see if this approach is safe and effective at controlling the cancer while reducing common side effects like incontinence and sexual problems.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: MRI-guided transurethral ultrasound ablation (device)
What this could lead to: If successful, this could offer a precise, less invasive treatment option for localized prostate cancer with fewer side effects on urinary and sexual function.
What could go wrong: This is an early-stage study with only 62 participants, so results may not apply to all patients. Risks include potential incomplete tumor destruction or side effects from the procedure.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LOCALIZED PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

prostate cancer prostate carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LOCALIZED PROSTATE CANCER

Contacts and locations

Locations

Department of Urology, VSSHP, University of Turku

Turku, Finland

More trials for these conditions

Other studies related to the condition(s) this trial covers.